Soligenix (OTC: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company has two active business segments. The BioTherapeutics segment is developing a photo-dynamic therapy for the treatment of cutaneous T-cell lymphoma, and proprietary formulations for the prevention/treatment of gastrointestinal disorders. The Vaccines/BioDefense segment has active development programs for a ricin toxin vaccine, an anthrax vaccine, OrbeShield, a GI acute radiation syndrome therapeutic candidate, and SGX943, a melioidosis therapeutic candidate. For more information, visit the company’s website at www.soligenix.com